GO:0006204 IMP catabolic process: Purine Nucleotide Degradation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006204 IMP catabolic process describes the chemical reactions and pathways that break down inosine monophosphate (IMP), a central purine nucleotide.
• IMP catabolism is a branch of purine nucleotide metabolism that controls cellular nucleotide pools and feeds salvage and uric acid pathways.
• Key enzymes include IMP-GMP 5'-nucleotidase, which hydrolyzes IMP to inosine, and downstream purine nucleoside phosphorylase and xanthine oxidase.
• Dysregulated IMP catabolism is linked to cancer cell proliferation, metabolic stress, and altered purine homeostasis.
• Gut microbial metabolites such as imidazole propionate intersect with purine metabolism and influence systemic disease, including Alzheimer's pathology and obesity.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of IMP catabolic enzymes in disease and metabolism.
Description
Inosine monophosphate (IMP) is a purine nucleotide at the crossroads of de novo purine synthesis and purine salvage. The Gene Ontology term GO:0006204, IMP catabolic process, defines the chemical reactions and pathways resulting in the breakdown of IMP. This process is essential for balancing nucleotide pools, recycling purine bases, and producing downstream metabolites such as inosine, hypoxanthine, xanthine, and uric acid. Researchers study IMP catabolism because it influences cell proliferation, metabolic stress responses, and disease states ranging from cancer to neurodegeneration. The enzymatic machinery of IMP catabolism includes IMP-GMP 5'-nucleotidase, which converts IMP to inosine, and subsequent enzymes that channel purine metabolites into salvage or excretion routes. Beyond classical purine metabolism, recent work shows that microbial and host purine intermediates, such as imidazole propionate, can modulate disease pathology, highlighting the broader physiological relevance of IMP-related pathways. Understanding GO:0006204 therefore provides a framework for interrogating how cells manage purine flux and how this flux contributes to human disease.
IMP catabolic process At A Glance
| GO ID | GO:0006204 |
|---|---|
| GO term | IMP catabolic process |
| Ontology | biological_process |
| Synonym | IMP breakdown; IMP catabolism; IMP degradation |
| Major function | Breakdown of inosine monophosphate (IMP) into downstream purine metabolites |
| Key enzymes | IMP-GMP 5'-nucleotidase; purine nucleoside phosphorylase; xanthine oxidase |
| Pathway context | Purine nucleotide metabolism; purine salvage and uric acid production |
| Disease relevance | Cancer, metabolic disorders, neurodegeneration, obesity |
What Is GO:0006204?
GO:0006204 IMP catabolic process is defined by the Gene Ontology as the chemical reactions and pathways resulting in the breakdown of IMP, inosine monophosphate. In practical terms, it encompasses the enzymatic steps that degrade IMP into downstream purine metabolites, including inosine, hypoxanthine, xanthine, and uric acid, as well as the regulatory mechanisms that control these reactions.
Why Is IMP catabolic process Important in Cell Biology?
IMP catabolic process is important because it controls the cellular levels of purine nucleotides and their degradation products, which are critical for DNA/RNA synthesis, energy metabolism, and signaling. Dysregulation of this pathway can alter nucleotide availability, affect cell proliferation, and contribute to disease phenotypes such as tumor growth and metabolic dysfunction. Moreover, microbial and host metabolites linked to purine metabolism, such as imidazole propionate, can influence systemic conditions including Alzheimer's disease and obesity, underscoring the broad biomedical significance of IMP catabolism.
• Maintains purine nucleotide homeostasis by removing excess IMP.
• Supplies inosine and hypoxanthine for purine salvage and uric acid production.
• Impacts cancer cell proliferation through regulation of nucleotide pools.
• Connects to metabolic stress responses and AMPK activation via purine intermediates.
• Modulates gut microbial metabolite effects on host metabolism and disease.
• Provides targets for therapeutic intervention in hyperuricemia and gout.
• Influences neuroinflammatory and neurodegenerative processes through purine metabolites.
• Serves as a model for studying enzyme regulation via cystathionine beta-synthase domains.
• Relevant to antiviral and host-pathogen interactions involving purine metabolism.
• Enables CRISPR-based functional genomics of purine catabolic enzymes.
What Happens During IMP catabolic process?
Dephosphorylation of IMP to Inosine
In simple terms: IMP loses its phosphate group to become inosine.
The first committed step in IMP catabolism is the hydrolysis of IMP to inosine, catalyzed by IMP-GMP 5'-nucleotidase. This enzyme removes the 5'-phosphate group, generating inosine and inorganic phosphate. IMP-GMP 5'-nucleotidase is a key regulator of purine nucleotide pools and is widely expressed in mammalian tissues.
Phosphorolysis of Inosine to Hypoxanthine
In simple terms: Inosine is further broken down to hypoxanthine.
Inosine is subsequently cleaved by purine nucleoside phosphorylase to yield hypoxanthine and ribose-1-phosphate. This step links IMP catabolism to purine salvage and to the generation of hypoxanthine, a substrate for xanthine oxidase.
Oxidation of Hypoxanthine to Xanthine and Uric Acid
In simple terms: Hypoxanthine is oxidized to xanthine and then to uric acid.
Hypoxanthine is oxidized by xanthine oxidase to xanthine, which is further oxidized to uric acid. These reactions represent the terminal steps of purine catabolism and are important for nitrogen excretion and redox balance.
Regulation by Cystathionine Beta-Synthase Domains
In simple terms: Some enzymes in this pathway are controlled by regulatory domains.
Enzymes involved in purine metabolism can be regulated via cystathionine beta-synthase (CBS) domains, which sense cellular energy status and modulate catalytic activity. This type of regulation allows IMP catabolism to adapt to metabolic demands.
Integration with De Novo Purine Synthesis
In simple terms: IMP breakdown is coordinated with IMP synthesis.
IMP catabolism is reciprocally regulated with de novo purine synthesis. Inhibitors of de novo purine synthesis can promote AICAR-induced AMPK activation and glucose uptake, indicating crosstalk between purine biosynthetic and catabolic pathways.
Key Genes Involved in GO:0006204 IMP catabolic process
The following genes and proteins are experimentally implicated in IMP catabolic process and related purine metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NT5C2 | IMP-GMP 5'-nucleotidase; hydrolyzes IMP to inosine | Regulates purine nucleotide pools; target in cancer and metabolic studies |
| PNP | Purine nucleoside phosphorylase; converts inosine to hypoxanthine | Links IMP catabolism to salvage and uric acid production |
| XDH | Xanthine dehydrogenase/oxidase; oxidizes hypoxanthine to xanthine and uric acid | Terminal step of purine catabolism; drug target for gout |
| IMPDH1 | Inosine monophosphate dehydrogenase 1; converts IMP to XMP | Competes with catabolism; regulates guanine nucleotide synthesis |
| IMPDH2 | Inosine monophosphate dehydrogenase 2; converts IMP to XMP | Dephosphorylation under FGFR signaling promotes S-phase progression |
| ADSL | Adenylosuccinate lyase; purine biosynthesis | Mutations cause purine metabolism disorders |
| ATIC | AICAR transformylase/IMP cyclohydrolase; de novo purine synthesis | Target of inhibitors that activate AMPK |
| GART | Phosphoribosylglycinamide formyltransferase; purine synthesis | Involved in de novo purine pathway |
| PFAS | Phosphoribosylformylglycinamidine synthase; purine synthesis | Purine biosynthesis enzyme |
| PAICS | Phosphoribosylaminoimidazole carboxylase; purine synthesis | Purine biosynthesis enzyme |
| PPAT | Phosphoribosyl pyrophosphate amidotransferase; first step of purine synthesis | Regulates flux into purine pathways |
| CBS | Cystathionine beta-synthase domain-containing proteins | Regulate enzymes via energy-sensing domains |
| ENTPD1 | Ectonucleoside triphosphate diphosphohydrolase 1 | Modulates extracellular purine metabolism |
| NT5E | Ecto-5'-nucleotidase (CD73) | Generates adenosine from AMP; related to purine catabolism |
| ADA | Adenosine deaminase; purine catabolism | Deficiency causes severe combined immunodeficiency |
| HPRT1 | Hypoxanthine phosphoribosyltransferase 1; purine salvage | Deficiency causes Lesch-Nyhan syndrome |
| GUK1 | Guanylate kinase; purine nucleotide metabolism | Maintains nucleotide pools |
How Is IMP catabolic process Regulated?
IMP catabolic process is regulated at multiple levels. Enzyme activity of IMP-GMP 5'-nucleotidase can be modulated by cellular energy status and by cystathionine beta-synthase domains that sense adenine nucleotides. In cancer cells, IMPDH2 dephosphorylation downstream of FGFR signaling promotes S-phase progression, indirectly affecting IMP availability for catabolism. Additionally, inhibition of de novo purine synthesis can shift purine flux and activate AMPK, linking purine metabolism to energy sensing. Microbial metabolites such as imidazole propionate can also influence host purine-related pathways, suggesting systemic regulation.
IMP catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IMPDH2 | Cancer cell proliferation | Knockout or point mutation in cancer cell lines |
| NT5C2 | Purine metabolism disorders | Knockout in HEK293 or HepG2 cells |
| PNP | Immunodeficiency | Knock-in of patient mutations in iPSCs |
| XDH | Gout and hyperuricemia | Overexpression in hepatocytes |
| HPRT1 | Lesch-Nyhan syndrome | Knockout in neuronal cells |
Cancer and Cell Proliferation
IMP catabolism intersects with cancer biology through regulation of nucleotide pools. IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth, indicating that purine metabolic enzymes can drive proliferation. Targeting IMP catabolic enzymes may therefore alter cancer cell viability.
Metabolic Disorders and Obesity
Imidazole propionate, a gut microbial metabolite, ameliorates lipid metabolism in adipocytes and attenuates high-fat diet-induced obesity via PPAR signaling, linking purine-related metabolites to metabolic regulation. This suggests that IMP catabolic pathways may influence systemic metabolism.
Neurodegeneration
Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology, indicating that purine-related microbial metabolites can impact neurodegeneration. IMP catabolism may thus contribute to neuroinflammatory processes.
Purine Metabolism Disorders
Defects in purine catabolic enzymes such as ADA and HPRT1 cause severe immunodeficiencies and neurological disorders, highlighting the clinical importance of this pathway.
From IMP catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NT5C2 alter IMP catabolism? | CRISPR knockout in HEK293T cells |
| Does IMPDH2 phosphorylation affect S-phase? | Point mutation knock-in of phospho-deficient IMPDH2 |
| Can IMP catabolism be monitored in live cells? | Tagged knock-in of NT5C2 with fluorescent reporter |
| Does overexpression of XDH increase uric acid? | Overexpression in HepG2 cells |
| What is the role of PNP in immune cells? | Knockout in Jurkat T cells |
| How does imidazole propionate affect purine flux? | Metabolomics in adipocytes |
How to Study the IMP catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of IMP, inosine, hypoxanthine, xanthine, uric acid | Quantify IMP catabolic flux |
| Enzyme activity assay | Conversion of IMP to inosine | Measure NT5C2 activity |
| CRISPR knockout screen | Gene essentiality for purine metabolism | Identify novel regulators |
| RNA-seq | Transcript levels of purine enzymes | Assess pathway regulation |
| Proteomics | Protein abundance and modifications | Detect IMPDH2 phosphorylation |
| Stable isotope tracing | Metabolic flux through purine pathways | Map IMP catabolism |
| Immunofluorescence | Subcellular localization of enzymes | Study NT5C2 localization |
| Western blot | Protein expression and phosphorylation | Validate CRISPR models |
Metabolomics and Flux Analysis
Liquid chromatography-mass spectrometry (LC-MS) can quantify IMP, inosine, hypoxanthine, xanthine, and uric acid to assess IMP catabolic flux. Stable isotope tracing can reveal pathway dynamics.
Enzymatic Activity Assays
In vitro assays using recombinant IMP-GMP 5'-nucleotidase or cell lysates measure the conversion of IMP to inosine, providing direct readouts of catabolic activity.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes required for IMP catabolism and purine homeostasis, enabling unbiased discovery of pathway regulators.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal expression changes in purine metabolic enzymes under conditions such as FGFR signaling or metabolic stress.
How CRISPR Can Be Used to Study GO:0006204 IMP catabolic process
Knockout
CRISPR knockout of NT5C2, PNP, or XDH can abolish specific steps of IMP catabolism, allowing researchers to measure downstream metabolite changes and cellular phenotypes.
Point Mutation
Point mutations can be introduced into IMPDH2 to mimic or prevent phosphorylation, testing its role in S-phase progression and tumor growth.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous NT5C2 or PNP loci enables real-time tracking of enzyme localization and interactions.
Overexpression
Overexpression of XDH or NT5C2 can increase purine catabolic flux, modeling hyperuricemia or altered nucleotide pools.
How EDITGENE Supports IMP catabolic process Research
Researchers studying IMP catabolic process-related genes often need to determine whether a candidate gene is causally involved in purine metabolism, disease progression, or drug response. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for IMP catabolic process research.
Frequently Asked Questions About IMP catabolic process
What is IMP catabolic process?
IMP catabolic process (GO:0006204) is the set of chemical reactions and pathways that break down inosine monophosphate (IMP) into downstream purine metabolites such as inosine, hypoxanthine, xanthine, and uric acid.
What genes are involved in IMP catabolic process?
Key genes include NT5C2 (IMP-GMP 5'-nucleotidase), PNP (purine nucleoside phosphorylase), XDH (xanthine dehydrogenase/oxidase), and IMPDH1/2, which regulate IMP levels.
How is IMP catabolism regulated?
It is regulated by enzyme expression, post-translational modifications such as IMPDH2 phosphorylation, and energy-sensing domains like cystathionine beta-synthase domains.
Why is IMP catabolic process important in cancer?
IMP catabolism controls nucleotide pools; IMPDH2 dephosphorylation promotes S-phase progression and tumor growth, making this pathway relevant to cancer.
What diseases are linked to IMP catabolism?
Disorders include cancer, hyperuricemia/gout, immunodeficiencies from ADA or PNP deficiency, and neurodegeneration linked to microbial metabolites.
How can I study IMP catabolic process using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of NT5C2, PNP, XDH, and IMPDH2 in cell lines.
What methods measure IMP catabolism?
LC-MS metabolomics, enzyme activity assays, stable isotope tracing, and CRISPR screens are commonly used.
What is the role of NT5C2 in IMP catabolism?
NT5C2 encodes IMP-GMP 5'-nucleotidase, which hydrolyzes IMP to inosine, a key step in IMP catabolism.
Does gut microbiota affect IMP catabolism?
Microbial metabolites such as imidazole propionate can influence host purine metabolism and disease pathology, including Alzheimer's and obesity.
How does EDITGENE support IMP catabolic process research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for purine metabolism genes.
Conclusion
GO:0006204 IMP catabolic process is a fundamental purine degradation pathway with broad implications for cancer, metabolic disorders, and neurodegeneration. Understanding its enzymes and regulation offers opportunities for therapeutic intervention. EDITGENE's CRISPR services empower researchers to dissect this pathway with precision.
References
- 1. Vemuganti V et al.. 2026. Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.. Nat Commun 17(1) PMID: 42362546
- 2. Itoh R. 1993. IMP-GMP 5'-nucleotidase.. Comp Biochem Physiol B 105(1):13-9 PMID: 8389266
- 4. Lin C et al.. 2025. Imidazole propionate ameliorates lipid metabolism in adipocytes to attenuate high-fat diet-induced obesity via PPAR signaling pathway.. Lipids Health Dis 24(1):356 PMID: 41204354
- 5. Zhou B et al.. 2025. IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth.. Cell Rep 44(1):115116 PMID: 39739531
- 6. Shi J et al.. 2023. Progress in the study of parvovirus entry pathway.. Virol J 20(1):61 PMID: 37016419
- 7. Anashkin VA et al.. 2017. Enzymes Regulated via Cystathionine β-Synthase Domains.. Biochemistry (Mosc) 82(10):1079-1087 PMID: 29037129
- 8. Dolinar K et al.. 2025. Diverse Inhibitors of De Novo Purine Synthesis Promote AICAR-Induced AMPK Activation and Glucose Uptake in L6 Myotubes.. Biofactors 51(4):e70037 PMID: 40793247
